newsfilter
← Latest News
Business Wire·

Definium Therapeutics Announces New Employee Inducement Grants

  • Definium Therapeutics issued inducement grants to two newly hired non-executive employees on July 20, 2026.
  • The grants consist of options to purchase an aggregate of 30,330 common shares of the Company.
  • The exercise price equals the closing price of Definium's common shares on the grant date.
  • Options vest over a four-year period with 25% vesting on the first anniversary & the remaining 75% vesting in monthly increments thereafter.
  • Grants were approved by the Compensation Committee on July 15, 2026, under Rule 5635(c)(4) of The NASDAQ Stock Market LLC.
  • The grants were made pursuant to Definium's 2026 Inducement Plan.
  • Definium is a late-stage clinical biopharmaceutical company focused on psychiatric & neurological disorders using psychedelics.
  • The company is headquartered in New York & trades on Nasdaq under the symbol DFTX.